Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope Orange County, shared a post on LinkedIn:
“A question that’s lingered for years:
dMMR/MSI-H immunotherapy… but can we induce it?
Can pMMR/MSS tumors be converted dMMR/MSI-H—and made responsive to IO?
Remarkably, this team has done it.
NP1867.”
Title: Pharmacological inhibition of PMS2 induces MMR deficiency and response to immune checkpoint blockade
Authors: Julian Blagg, Philippe Riou, Alexia Hervieu, Eleonora Piumatti, Maria T. Rodriguez-Plata, Paolo Battuello, Adam Peall, Vito Amodio, Pietro Paolo Vitiello, Daniel J. H. Nightingale, Ruzica Bago, Paige Tongue, Tessa Slater, Kalpesh Parmar, Pradip Patel, Javier Rodríguez González, David E. Clark, Gareth W. Langley, Charles Nichols, Alba Guarne, Paul C.M. Winship, Matthew Baker, Martin Drysdale, Giovanni Germano, Alberto Bardelli
Read the full article.
Other articles featuring Pashtoon Kasi on OncoDaily.